Sector News

Franz B. Humer, former chairman and CEO of Roche Group, appointed to Kite Pharma’s board of directors

September 16, 2015
Life sciences

(GLOBE NEWSWIRE) – Kite Pharma, Inc. (Kite) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd., has been appointed to the Company’s Board of Directors.

Dr. Humer stated, “Kite Pharma is at the forefront of advancing cancer T cell immunotherapy which, in my view, is one of the most promising new approaches in oncology. Kite’s programs have the potential to change the paradigm of cancer treatment, and I look forward to working closely with the accomplished team at Kite.”

Dr. Humer began his career in the pharmaceutical industry in 1973, joining Schering Plough Corporation where he held various General Management positions in Latin America and Europe. After leaving Schering Plough, he joined the Board of Glaxo Holdings plc and progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-US operations for 13 years. Subsequent to this, Dr. Humer served as Head of Pharmaceuticals and then as Chief Operating Officer of F. Hoffmann-La Roche Ltd., prior to his taking the helm as CEO at Roche Group (1998-2001) and then Chairman and CEO (2001-2008). His tenure as Chairman of Roche Holding Ltd. extended from 2008 to 2014.

Dr. Humer serves as Chairman of the Board of Directors of the International Centre for Missing and Exploited Children and the Humer Foundation.

He is also Chairman of Diageo plc, an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd. (Japan), Bial Pharmaceuticals (Portugal), WISeKey (Cyber Security Company, Switzerland) and a member of the International Advisory Board of Allianz SE.

In 2000, Dr. Humer received the Oliver R. Grace Award for distinguished service in advancing cancer research.

“Dr. Humer possesses unique experience within the pharmaceutical industry, including his 20-year tenure at Roche. During this period he transformed the company, including refining Roche’s focus on cancer therapies and completing the acquisition of Genentech,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. “We are deeply honored to welcome Franz, one of the most respected and revered pharma executives, to the Kite Pharma Board. We are excited to gain his unique insights as we continue to progress our cancer immunotherapy programs in development and toward commercialization.”

Source: Kite Pharma, Inc.

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach